The information at this site is a free service to the biomedical community. The goal is to provide a source of current information on sickle cell disease, thalassemia, and disorder of iron metabolism. The site includes basic and clinical research, management, and new developments in the fields.

Increasing levels of nitric oxide in the blood may offer new options for treating sickle cell anemia, the most common inherited blood disorder in the country. Researchers at the Warren Grant Magnuson Clinical Center at the National Institutes of Health are examining how nitric oxide acts on hemoglobin.

May 31, 1996 -- Ansan, Inc. today announced that it has received a notice from the U.S. Patent Office of its intent to grant a U.S. patent for the use of the Ansan drug Novaheme (AN10) for the treatment of red blood cell disorders such as sickle cell disease and beta thalassemia.